Role of chromatin assembly factor-1/p60 and poly [ADP-ribose] polymerase 1 in mycosis fungoides.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ analysis
Chromatin Assembly Factor-1
/ analysis
Female
Humans
Immunohistochemistry
Italy
Male
Middle Aged
Mycosis Fungoides
/ enzymology
Neoplasm Staging
Poly (ADP-Ribose) Polymerase-1
/ analysis
Predictive Value of Tests
Retrospective Studies
Risk Assessment
Risk Factors
Skin Neoplasms
/ enzymology
Time Factors
Treatment Outcome
Chromatin assembly factor-1
Cutaneous lymphoma
Mycosis fungoides
Poly [ADP-ribose] polymerase 1
Prognosis
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
30
07
2020
accepted:
14
10
2020
revised:
16
09
2020
pubmed:
25
10
2020
medline:
18
5
2021
entrez:
24
10
2020
Statut:
ppublish
Résumé
Mycosis fungoides (MF) represents the most common type of cutaneous lymphoma. In the majority of patients, the disease has a slow evolution and a protracted course; however, a subset of patients shows poor oncologic outcomes. Unfortunately, there are no reliable prognostic markers for MF, and the currently available treatments are only effective in a minority of patients. This study aimed to evaluate the expression and clinical significance of PARP-1 and CAF-1/p60 in MF. Sixty-four MF representatives of the different stages of disease were assessed by immunohistochemistry for PARP-1 and CAF-1/p60. The association of PARP-1 and CAF-1/p60 with the MF stage and outcome was assessed by using Fisher's exact test and Kaplan-Meier survival analysis with the Log-rank test; a p value < 0.05 was considered significant. PARP-1 was overexpressed in 57.9% of MF and was significantly associated with a MF stage > II (p = 0.034) but not with the risk of death (p = 0.237). CAF-1/p60 was overexpressed in 26.8% of MF and was significantly associated with decreased overall survival (p < 0.001) but not with the MF stage (p = 1). A significant association was found between PARP-1 overexpression and CAF-1/p60 overexpression (p = 0.0025). Simultaneous overexpression of PARP-1 and CAF-1/p60 was significantly associated with decreased overall survival (p < 0.001), although less strongly than CAF-1/p60 alone (χ
Identifiants
pubmed: 33098490
doi: 10.1007/s00428-020-02952-z
pii: 10.1007/s00428-020-02952-z
pmc: PMC8099834
doi:
Substances chimiques
Biomarkers, Tumor
0
CHAF1A protein, human
0
Chromatin Assembly Factor-1
0
PARP1 protein, human
EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1
EC 2.4.2.30
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
961-968Références
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768–3785. https://doi.org/10.1182/blood-2004-09-3502
doi: 10.1182/blood-2004-09-3502
pubmed: 15692063
Swerdlow SH et al. (2017) WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon, France. World Health Organization Calssification of Tumors of Haematopoietic and Lymphoid Tissue. doi: https://doi.org/10.1017/CBO9781107415324.004
Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, Gniadecki R, Klemke CD, Ortiz-Romero PL, Papadavid E, Pimpinelli N, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Väkevä L, Vermeer MH, Whittaker S, Willemze R, Knobler R (2017) European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - update 2017. Eur J Cancer 77:57–74
pubmed: 28365528
doi: 10.1016/j.ejca.2017.02.027
Korgavkar K, Xiong M, Weinstock M (2013) Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol 149(11):1295–1299
pubmed: 24005876
doi: 10.1001/jamadermatol.2013.5526
Su C, Nguyen KA, Bai HX et al (2017) Racial disparity in mycosis fungoides: an analysis of 4495 cases from the US National Cancer Database. J Am Acad Dermatol 77(3):497–502 e2
pubmed: 28645647
doi: 10.1016/j.jaad.2017.04.1137
Fink-Puches R, Chott A, Ardigo M, Simonitsch I, Ferrara G, Kerl H, Cerroni L (2004) The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr Dermatol 21:525–533. https://doi.org/10.1111/j.0736-8046.2004.21500.x
doi: 10.1111/j.0736-8046.2004.21500.x
pubmed: 15461755
Virmani P, Myskowski PL, Pulitzer M (2016) Unusual variants of mycosis fungoides. Diagn Histopathol (Oxf) 22(4):142–151
doi: 10.1016/j.mpdhp.2016.04.004
Fabbrocini G, Mazzella C, Cantelli M, Baldo A, Russo D, de Rosa G, Monfrecola G (2018) Reflectance confocal microscopy as new diagnostic tool in folliculotropic mycosis fungoides. Skin Appendage Disord 4(2):118–121
pubmed: 29765972
doi: 10.1159/000479822
Mascolo M, Romano MF, Ilardi G, Romano S, Baldo A, Scalvenzi M, Argenziano G, Merolla F, Russo D, Varricchio S, Pagliuca F, Russo M, Ciancia G, de Rosa G, Staibano S (2018) Expression of FK506-binding protein 51 (FKBP51) in mycosis fungoides. J Eur Acad Dermatol Venereol 32(5):735–744
pubmed: 28977697
doi: 10.1111/jdv.14614
Scarisbrick JJ, Kim YH, Whittaker SJ, Wood GS, Vermeer MH, Prince HM, Quaglino P (2014) Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? Br J Dermatol 170(6):1226–1236
pubmed: 24641480
doi: 10.1111/bjd.12909
Benner MF, Jansen PM, Vermeer MH, Willemze R (2012) Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 119(7):1643–1649
pubmed: 22160616
doi: 10.1182/blood-2011-08-376319
Larocca C, Kupper T (2019) Mycosis fungoides and Sézary syndrome: an update. Hematol Oncol Clin North Am 33(1):103–120
pubmed: 30497668
pmcid: 7147244
doi: 10.1016/j.hoc.2018.09.001
Hanel W, Briski R, Ross CW, Anderson TF, Kaminski MS, Hristov AC, Wilcox RA (2016) A retrospective comparative outcome analysis following systemic therapy in mycosis fungoides and Sezary syndrome. Am J Hematol 91(12):E491–E495
pubmed: 27649045
doi: 10.1002/ajh.24564
Wilcox RA (2018) Cutaneous B-cell lymphomas: 2019 update on diagnosis, risk stratification, and management. Am J Hematol 93(11):1427–1430
pubmed: 30039522
doi: 10.1002/ajh.25224
Hughes CF, Khot A, McCormack C et al (2015) Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood. 125(1):71–81
pubmed: 25336628
doi: 10.1182/blood-2014-07-588236
Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, Ferrant A, Kobbe G, Narni F, Deliliers GL, Olavarría E, Schmitz N, Sureda A (2010) Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 28(29):4492–4499
pubmed: 20697072
doi: 10.1200/JCO.2010.29.3241
Tan RS, Butterworth CM, McLaughlin H, Malka S, Samman PD (1974) Mycosis fungoides--a disease of antigen persistence. Br J Dermatol 91(6):607–616
pubmed: 4281316
doi: 10.1111/j.1365-2133.1974.tb12449.x
Wohl Y, Tur E (2007) Environmental risk factors for mycosis fungoides. Curr Probl Dermatol 35:52–64
pubmed: 17641490
doi: 10.1159/000106410
McGirt LY, Adams CM, Baerenwald DA, Zwerner JP, Zic JA, Eischen CM (2014) miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma. J Invest Dermatol 134(4):1101–1107
pubmed: 24304814
doi: 10.1038/jid.2013.461
Quaglino P, Pimpinelli N, Berti E, Calzavara-Pinton P, Alfonso Lombardo G, Rupoli S, Alaibac M, Bottoni U, Carbone A, Fava P, Fimiani M, Mamusa AM, Titli S, Zinzani PL, Bernengo MG, on behalf of the Gruppo Italiano Linfomi Cutanei (GILC) (2012) Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer. 118(23):5830–5839
pubmed: 22674564
doi: 10.1002/cncr.27627
Lindahl LM, Besenbacher S, Rittig AH, Celis P, Willerslev-Olsen A, Gjerdrum LMR, Krejsgaard T, Johansen C, Litman T, Woetmann A, Odum N, Iversen L (2018) Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. Blood. 131(7):759–770
pubmed: 29208599
doi: 10.1182/blood-2017-06-788950
de Masson A, O’Malley JT, Elco CP et al (2018) High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides. Sci Transl Med 10(440):eaar5894
pubmed: 29743350
pmcid: 6366329
doi: 10.1126/scitranslmed.aar5894
Wehkamp U, Weichenthal M, Egberts F, Schwarz T, Klapper W, Oschlies I (2018) Clinically defined subgroups of mycosis fungoides display differing histopathological features at initial biopsy. Leuk Lymphoma 59(12):2871–2879
pubmed: 29616855
doi: 10.1080/10428194.2018.1452218
Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH (2015) Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol 33(32):3766–3773
pubmed: 26438120
pmcid: 4979132
doi: 10.1200/JCO.2015.61.7142
Lemchak D, Banerjee S, Digambar SS, Hood BL, Conrads TP, Jedrych J, Geskin L, Akilov OE (2018) Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. Exp Dermatol 27(2):188–190
pubmed: 29205518
doi: 10.1111/exd.13477
Amé JC, Spenlehauer C, de Murcia G (2004) The PARP superfamily. Bioessays. 26(8):882–893
pubmed: 15273990
doi: 10.1002/bies.20085
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [published correction appears in Nature. 2007 May 17;447(7142):346]. Nature. 434(7035):913–917
Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NMB, Jackson SP, Smith GCM, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434(7035):917–921
pubmed: 15829967
doi: 10.1038/nature03445
Yang L, Huang K, Li X, du M, Kang X, Luo X, Gao L, Wang C, Zhang Y, Zhang C, Tong Q, Huang K, Zhang F, Huang D (2013) Identification of poly(ADP-ribose) polymerase-1 as a cell cycle regulator through modulating Sp1 mediated transcription in human hepatoma cells. PLoS One 8(12):e82872
pubmed: 24367566
pmcid: 3868549
doi: 10.1371/journal.pone.0082872
Ray Chaudhuri A, Hashimoto Y, Herrador R, Neelsen KJ, Fachinetti D, Bermejo R, Cocito A, Costanzo V, Lopes M (2012) Topoisomerase I poisoning results in PARP-mediated replication fork reversal. Nat Struct Mol Biol 19(4):417–423
pubmed: 22388737
doi: 10.1038/nsmb.2258
Rouleau M, Aubin RA, Poirier GG (2004) Poly(ADP-ribosyl)ated chromatin domains: access granted. J Cell Sci 117(Pt 6):815–825
pubmed: 14963022
doi: 10.1242/jcs.01080
Volk A, Crispino JD (2015) The role of the chromatin assembly complex (CAF-1) and its p60 subunit (CHAF1b) in homeostasis and disease. Biochim Biophys Acta 1849(8):979–986
pubmed: 26066981
pmcid: 4515380
doi: 10.1016/j.bbagrm.2015.05.009
Ozanne SE, Constância M (2007) Mechanisms of disease: the developmental origins of disease and the role of the epigenotype. Nat Clin Pract Endocrinol Metab 3(7):539–546
pubmed: 17581623
doi: 10.1038/ncpendmet0531
pmcid: 17581623
Ehrenhofer-Murray AE (2004) Chromatin dynamics at DNA replication, transcription and repair. Eur J Biochem 271(12):2335–2349
pubmed: 15182349
doi: 10.1111/j.1432-1033.2004.04162.x
pmcid: 15182349
Verreault A, Kaufman PD, Kobayashi R, Stillman B (1996) Nucleosome assembly by a complex of CAF-1 and acetylated histones H3/H4. Cell. 87(1):95–104
pubmed: 8858152
doi: 10.1016/S0092-8674(00)81326-4
pmcid: 8858152
Zhu Q, Wani G, Arab HH, El-Mahdy MA, Ray A, Wani AA (2009) Chromatin restoration following nucleotide excision repair involves the incorporation of ubiquitinated H2A at damaged genomic sites. DNA Repair (Amst) 8(2):262–273
doi: 10.1016/j.dnarep.2008.11.007
Tagami H, Ray-Gallet D, Almouzni G, Nakatani Y (2004) Histone H3.1 and H3.3 complexes mediate nucleosome assembly pathways dependent or independent of DNA synthesis. Cell. 116(1):51–61
pubmed: 14718166
doi: 10.1016/S0092-8674(03)01064-X
pmcid: 14718166
Ramirez-Parra E, Gutierrez C (2007) The many faces of chromatin assembly factor 1. Trends Plant Sci 12(12):570–576
pubmed: 17997123
doi: 10.1016/j.tplants.2007.10.002
pmcid: 17997123
Gaillard PHL, Martini EM, Kaufman PD, Stillman B, Moustacchi E, Almouzni G (1996) Chromatin assembly coupled to DNA repair: a new role for chromatin assembly factor I. Cell. 86(6):887–896
pubmed: 8808624
doi: 10.1016/S0092-8674(00)80164-6
pmcid: 8808624
Linger JG, Tyler JK (2007) Chromatin disassembly and reassembly during DNA repair. Mutat Res 618(1–2):52–64
pubmed: 17303193
pmcid: 2593076
doi: 10.1016/j.mrfmmm.2006.05.039
Verger A, Crossley M (2004) Chromatin modifiers in transcription and DNA repair. Cell Mol Life Sci 61(17):2154–2162
pubmed: 15338045
doi: 10.1007/s00018-004-4176-y
Polo SE, Theocharis SE, Klijanienko J, Savignoni A, Asselain B, Vielh P, Almouzni G (2004) Chromatin assembly factor-1, a marker of clinical value to distinguish quiescent from proliferating cells. Cancer Res 64(7):2371–2381
pubmed: 15059888
doi: 10.1158/0008-5472.CAN-03-2893
Polo SE, Theocharis SE, Grandin L, Gambotti L, Antoni G, Savignoni A, Asselain B, Patsouris E, Almouzni G (2010) Clinical significance and prognostic value of chromatin assembly factor-1 overexpression in human solid tumours. Histopathology. 57(5):716–724
pubmed: 21083601
doi: 10.1111/j.1365-2559.2010.03681.x
Mesolella M, Iorio B, Landi M, Cimmino M, Ilardi G, Iengo M, Mascolo M (2017) Overexpression of chromatin assembly factor-1/p60 predicts biological behaviour of laryngeal carcinomas. L’espressività della proteina CAF-1 p60 come fattore prognostico nei carcinomi laringei. Acta Otorhinolaryngol Ital 37(1):17–24
pubmed: 28374866
pmcid: 5384305
doi: 10.14639/0392-100X-867
Mascolo M, Ilardi G, Merolla F, Russo D, Vecchione ML, de Rosa G, Staibano S (2012) Tissue microarray-based evaluation of chromatin assembly factor-1 (CAF-1)/p60 as tumour prognostic marker. Int J Mol Sci 13(9):11044–11062
pubmed: 23109837
pmcid: 3472729
doi: 10.3390/ijms130911044
Mascolo M, Ilardi G, Romano MF, Celetti A, Siano M, Romano S, Luise C, Merolla F, Rocco A, Vecchione ML, de Rosa G, Staibano S (2012) Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer. Histopathology. 61(6):1089–1105
pubmed: 22882088
pmcid: 3546388
doi: 10.1111/j.1365-2559.2012.04313.x
Staibano S, Mascolo M, Rocco A, Lo Muzio L, Ilardi G, Siano M, Pannone G, Vecchione ML, Nugnes L, Califano L, Zamparese R, Bufo P, de Rosa G (2011) The proliferation marker chromatin assembly factor-1 is of clinical value in predicting the biological behaviour of salivary gland tumours. Oncol Rep 25(1):13–22
pubmed: 21109952
Mascolo M, Vecchione ML, Ilardi G, Scalvenzi M, Molea G, di Benedetto M, Nugnes L, Siano M, de Rosa G, Staibano S (2010) Overexpression of chromatin assembly factor-1/p60 helps to predict the prognosis of melanoma patients. BMC Cancer 10:63
pubmed: 20178651
pmcid: 2843674
doi: 10.1186/1471-2407-10-63
Staibano S, Mascolo M, Mancini FP, Kisslinger A, Salvatore G, di Benedetto M, Chieffi P, Altieri V, Prezioso D, Ilardi G, de Rosa G, Tramontano D (2009) Overexpression of chromatin assembly factor-1 (CAF-1) p60 is predictive of adverse behaviour of prostatic cancer. Histopathology. 54(5):580–589
pubmed: 19309489
doi: 10.1111/j.1365-2559.2009.03266.x
Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM (2010) Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. Genes Cancer 1(8):812–821
pubmed: 3092251
pmcid: 3092251
doi: 10.1177/1947601910383418
Morra F, Merolla F, Picardi I et al (2019) CAF-1 subunits levels suggest combined treatments with PARP-inhibitors and ionizing radiation in advanced HNSCC. Cancers (Basel). 11(10):1582
pmcid: 6827109
doi: 10.3390/cancers11101582
pubmed: 6827109